This biotechnology company develops molecules aimed at preventing and reversing neurodegenerative diseases through neural regeneration techniques. By providing healthcare professionals with novel therapeutic options, the company addresses the critical need for effective treatments for conditions like Alzheimer's and Parkinson's disease.
Funding
$550K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Neurodegenerative diseases like Alzheimer's and Parkinson's, characterized by progressive neuronal damage and loss of cognitive and motor function, present a significant unmet medical need. Current therapeutic options often provide only symptomatic relief without addressing the underlying disease mechanisms or promoting neural repair. The lack of disease-modifying treatments contributes to the high healthcare costs and devastating impact on patients and their families.
Solution
Phanesbiotech is developing novel therapeutic platforms aimed at preventing and reversing neurodegenerative diseases by promoting neuroregeneration and modulating key pathological processes. Their lead molecule, P021, enhances the activity of brain-derived neurotrophic factor (BDNF) while inhibiting leukemia inhibiting factor (LIF), shifting the balance from neurodegeneration to neuroregeneration. This approach promotes neural formation and neuronal plasticity, preventing nerve cell destruction and facilitating the repair of damaged cells. Additionally, Phanesbiotech is developing PB43D, a potent tau antibody for immunotherapy, designed to clear both tau and amyloid-beta pathologies associated with Alzheimer's disease and related tauopathies.
Target Audience
The primary target audience includes healthcare professionals, such as neurologists and geriatricians, involved in the treatment of neurodegenerative diseases, as well as patients diagnosed with Alzheimer's disease, Parkinson's disease, and related tauopathies.
Features
- P021: A small molecule that enhances BDNF activity and inhibits LIF, promoting neurogenesis and neuronal plasticity.
- P021: Demonstrated in preclinical studies to prevent cognitive deficits and reduce tau and amyloid-beta pathologies in Alzheimer's disease models.
- PB43D: A humanizable IgG1 isotype antibody for passive immunotherapy targeting tau pathology.
- PB43D: Shown to clear both tau and amyloid-beta pathologies and rescue cognitive impairment in a transgenic mouse model of Alzheimer's disease and tauopathy.
- PB43D: Designed for intravenous administration with plasma and cerebrospinal fluid levels of tau and amyloid-beta serving as biomarkers for target engagement and efficacy.